Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 202

1.

Valproate and Retinoic Acid in Combination With Decitabine in Elderly Nonfit Patients With Acute Myeloid Leukemia: Results of a Multicenter, Randomized, 2 × 2, Phase II Trial.

Lübbert M, Grishina O, Schmoor C, Schlenk RF, Jost E, Crysandt M, Heuser M, Thol F, Salih HR, Schittenhelm MM, Germing U, Kuendgen A, Götze KS, Lindemann HW, Müller-Tidow C, Heil G, Scholl S, Bug G, Schwaenen C, Giagounidis A, Neubauer A, Krauter J, Brugger W, De Wit M, Wäsch R, Becker H, May AM, Duyster J, Döhner K, Ganser A, Hackanson B, Döhner H; DECIDER Study Team.

J Clin Oncol. 2019 Dec 3:JCO1901053. doi: 10.1200/JCO.19.01053. [Epub ahead of print]

PMID:
31794324
2.

Time from first symptom onset to the final diagnosis of multiple myeloma (MM) - possible risks and future solutions: retrospective and prospective 'Deutsche Studiengruppe MM' (DSMM) and 'European Myeloma Network' (EMN) analysis.

Graziani G, Herget GW, Ihorst G, Zeissig M, Chaidos A, Auner HW, Duyster J, Wäsch R, Engelhardt M.

Leuk Lymphoma. 2019 Nov 28:1-12. doi: 10.1080/10428194.2019.1695051. [Epub ahead of print]

PMID:
31779510
3.

A novel conditional NPM-ALK-driven model of CD30+ T-cell lymphoma mediated by a translational stop cassette.

Shoumariyeh K, Schneider N, Poggio T, Veratti P, Ehrenfeld S, Redhaber DM, Khan R, Pfeifer D, Klingeberg C, Kreutmair S, Rudelius M, Quintanilla-Martinez L, Fend F, Illert AL, Duyster J, Miething C.

Oncogene. 2019 Nov 21. doi: 10.1038/s41388-019-1058-1. [Epub ahead of print]

PMID:
31754210
4.

Immunization against poly-N-acetylglucosamine reduces neutrophil activation and GVHD while sparing microbial diversity.

Hülsdünker J, Thomas OS, Haring E, Unger S, Gonzalo Núñez N, Tugues S, Gao Z, Duquesne S, Cywes-Bentley C, Oyardi O, Kirschnek S, Schmitt-Graeff A, Pabst O, Koenecke C, Duyster J, Apostolova P, Blaser MJ, Becher B, Pier GB, Häcker G, Zeiser R.

Proc Natl Acad Sci U S A. 2019 Oct 8;116(41):20700-20706. doi: 10.1073/pnas.1908549116. Epub 2019 Sep 16.

PMID:
31527267
5.

Venetoclax in combination with carfilzomib, doxorubicin and dexamethasone restores responsiveness in an otherwise treatment-refractory multiple myeloma patient.

Bojtine Kovacs S, Luan J, Dold SM, Weis A, Pantic M, Duyster J, Wäsch R, Engelhardt M.

Haematologica. 2019 Aug 29. pii: haematol.2019.232330. doi: 10.3324/haematol.2019.232330. [Epub ahead of print]

6.

Proteomic Phosphosite Analysis Identified Crucial NPM-ALK-Mediated NIPA Serine and Threonine Residues.

Gengenbacher A, Müller-Rudorf A, Poggio T, Gräßel L, Dumit VI, Kreutmair S, Lippert LJ, Duyster J, Illert AL.

Int J Mol Sci. 2019 Aug 20;20(16). pii: E4060. doi: 10.3390/ijms20164060.

7.

Phosphorylation of Beclin-1 by BCR-ABL suppresses autophagy in chronic myeloid leukemia.

Yu C, Gorantla SP, Müller-Rudorf A, Müller TA, Kreutmair S, Albers C, Jakob L, Lippert LJ, Yue Z, Engelhardt M, Follo M, Zeiser R, Huber TB, Duyster J, Illert AL.

Haematologica. 2019 Aug 8. pii: haematol.2018.212027. doi: 10.3324/haematol.2018.212027. [Epub ahead of print]

8.

TP53 abnormalities and chromosomal aneuploidy in acute panmyelosis with myelofibrosis.

Pantic M, Pfeifer D, Kapp-Schwoerer S, Ihorst G, Becker H, Zeiser R, Duyster J, Schmitt-Graeff A.

Leukemia. 2019 Dec;33(12):2956-2962. doi: 10.1038/s41375-019-0523-8. Epub 2019 Jul 26. No abstract available.

PMID:
31350530
9.

Phenotypical and functional analysis of donor lymphocyte infusion products after long-term cryopreservation.

Schäfer AK, Waterhouse M, Follo M, Duque-Afonso J, Duyster J, Bertz H, Finke J.

Transfus Apher Sci. 2019 Jul 10:102594. doi: 10.1016/j.transci.2019.06.022. [Epub ahead of print]

PMID:
31303510
10.

NPM1c alters FLT3-D835Y localization and signaling in acute myeloid leukemia.

Rudorf A, Müller TA, Klingeberg C, Kreutmair S, Poggio T, Gorantla SP, Rückert T, Schmitt-Graeff A, Gengenbacher A, Paschka P, Baldus C, Zeiser R, Vassiliou GS, Bradley A, Duyster J, Illert AL.

Blood. 2019 Jul 25;134(4):383-388. doi: 10.1182/blood.2018883140. Epub 2019 Jun 11.

11.

Clonal hematopoiesis of indeterminate potential in older patients having received an allogeneic stem cell transplantation from young donors.

Heumüller A, Wehrle J, Stosch J, Niemöller C, Bleul S, Waterhouse M, Uhl D, Metzeler KH, Lübbert M, Duyster J, Finke J, Becker H.

Bone Marrow Transplant. 2019 May 30. doi: 10.1038/s41409-019-0575-4. [Epub ahead of print] No abstract available.

PMID:
31147597
12.

Circulating cKIT and PDGFRA DNA indicates disease activity in Gastrointestinal Stromal Tumor (GIST).

Jilg S, Rassner M, Maier J, Waldeck S, Kehl V, Follo M, Philipp U, Sauter A, Specht K, Mitschke J, Lange T, Bauer S, Jost PJ, Peschel C, Duyster J, Gaiser T, Hohenberger P, von Bubnoff N.

Int J Cancer. 2019 Oct 15;145(8):2292-2303. doi: 10.1002/ijc.32282. Epub 2019 Apr 29.

PMID:
30882891
13.

Identification of enhancer of mRNA decapping 4 as a novel fusion partner of MLL in acute myeloid leukemia.

Becker H, Greve G, Kataoka K, Mallm JP, Duque-Afonso J, Ma T, Niemöller C, Pantic M, Duyster J, Cleary ML, Schüler J, Rippe K, Ogawa S, Lübbert M.

Blood Adv. 2019 Mar 12;3(5):761-765. doi: 10.1182/bloodadvances.2018023879. No abstract available.

14.

PIM1 inhibition effectively enhances plerixafor-induced HSC mobilization by counteracting CXCR4 upregulation and blocking CXCL12 secretion.

Müller TA, Pennisi S, Zwick A, Decker S, Klein C, Rister B, Rudorf A, Kissel S, Follo M, Wäsch R, Illert AL, Pfeifer D, Oostendorp R, Waskow C, Dierks C, Duyster J.

Leukemia. 2019 May;33(5):1296-1301. doi: 10.1038/s41375-019-0428-6. Epub 2019 Feb 28. No abstract available.

PMID:
30816332
15.

Avoiding chemotherapy prescribing errors: Analysis and innovative strategies.

Reinhardt H, Otte P, Eggleton AG, Ruch M, Wöhrl S, Ajayi S, Duyster J, Jung M, Hug MJ, Engelhardt M.

Cancer. 2019 May 1;125(9):1547-1557. doi: 10.1002/cncr.31950. Epub 2019 Jan 29.

PMID:
30695105
16.

Biology-Driven Approaches to Prevent and Treat Relapse of Myeloid Neoplasia after Allogeneic Hematopoietic Stem Cell Transplantation.

Zeiser R, Beelen DW, Bethge W, Bornhäuser M, Bug G, Burchert A, Christopeit M, Duyster J, Finke J, Gerbitz A, Klusmann JH, Kobbe G, Lübbert M, Müller-Tidow C, Platzbecker U, Rösler W, Sauer M, Schmid C, Schroeder T, Stelljes M, Kröger N, Müller LP.

Biol Blood Marrow Transplant. 2019 Apr;25(4):e128-e140. doi: 10.1016/j.bbmt.2019.01.016. Epub 2019 Jan 15. Review.

PMID:
30658222
17.

Droplet digital PCR for the simultaneous analysis of minimal residual disease and hematopoietic chimerism after allogeneic cell transplantation.

Waterhouse M, Pfeifer D, Duque-Afonso J, Follo M, Duyster J, Depner M, Bertz H, Finke J.

Clin Chem Lab Med. 2019 Apr 24;57(5):641-647. doi: 10.1515/cclm-2018-0827.

PMID:
30457973
18.
19.

APC/CCdh1 regulates the balance between maintenance and differentiation of hematopoietic stem and progenitor cells.

Ewerth D, Kreutmair S, Schmidts A, Ihorst G, Follo M, Wider D, Felthaus J, Schüler J, Duyster J, Illert AL, Engelhardt M, Wäsch R.

Cell Mol Life Sci. 2019 Jan;76(2):369-380. doi: 10.1007/s00018-018-2952-3. Epub 2018 Oct 24.

PMID:
30357422
20.

CBP Modulates Sensitivity to Dasatinib in Pre-BCR+ Acute Lymphoblastic Leukemia.

Duque-Afonso J, Lin CH, Han K, Morgens DW, Jeng EE, Weng Z, Jeong J, Wong SHK, Zhu L, Wei MC, Chae HD, Schrappe M, Cario G, Duyster J, Xiao X, Sakamoto KM, Bassik MC, Cleary ML.

Cancer Res. 2018 Nov 15;78(22):6497-6508. doi: 10.1158/0008-5472.CAN-18-1703. Epub 2018 Sep 27.

21.

Allogeneic transplantation of multiple myeloma patients may allow long-term survival in carefully selected patients with acceptable toxicity and preserved quality of life.

Greil C, Engelhardt M, Ihorst G, Schoeller K, Bertz H, Marks R, Zeiser R, Duyster J, Einsele H, Finke J, Wäsch R.

Haematologica. 2019 Feb;104(2):370-379. doi: 10.3324/haematol.2018.200881. Epub 2018 Sep 20.

22.

Current Immunotherapeutic Approaches in T Cell Non-Hodgkin Lymphomas.

Poggio T, Duyster J, Illert AL.

Cancers (Basel). 2018 Sep 18;10(9). pii: E339. doi: 10.3390/cancers10090339. Review.

23.

Decitabine in combination with donor lymphocyte infusions can induce remissions in relapsed myeloid malignancies with higher leukemic burden after allogeneic hematopoietic cell transplantation.

Sommer S, Cruijsen M, Claus R, Bertz H, Wäsch R, Marks R, Zeiser R, Bogatyreva L, Blijlevens NMA, May A, Duyster J, Huls G, van der Velden WJFM, Finke J, Lübbert M.

Leuk Res. 2018 Sep;72:20-26. doi: 10.1016/j.leukres.2018.07.005. Epub 2018 Jul 7.

PMID:
30064039
24.

Gene mutations and clonal architecture in myelodysplastic syndromes and changes upon progression to acute myeloid leukaemia and under treatment.

Stosch JM, Heumüller A, Niemöller C, Bleul S, Rothenberg-Thurley M, Riba J, Renz N, Szarc Vel Szic K, Pfeifer D, Follo M, Pahl HL, Zimmermann S, Duyster J, Wehrle J, Lübbert M, Metzeler KH, Claus R, Becker H.

Br J Haematol. 2018 Sep;182(6):830-842. doi: 10.1111/bjh.15461. Epub 2018 Jul 5.

PMID:
29974943
25.

Safety and efficacy of vorinostat, bortezomib, doxorubicin and dexamethasone in a phase I/II study for relapsed or refractory multiple myeloma (VERUMM study: vorinostat in elderly, relapsed and unfit multiple myeloma).

Waldschmidt JM, Keller A, Ihorst G, Grishina O, Müller S, Wider D, Frey AV, King K, Simon R, May A, Tassone P, Duyster J, Jung M, Raje N, Wäsch R, Engelhardt M.

Haematologica. 2018 Oct;103(10):e473-e479. doi: 10.3324/haematol.2018.189969. Epub 2018 Apr 19. No abstract available.

26.

Erratum: Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells.

Mathew NR, Baumgartner F, Braun L, O'Sullivan D, Thomas S, Waterhouse M, Müller TA, Hanke K, Taromi S, Apostolova P, Illert AL, Melchinger W, Duquesne S, Schmitt-Graeff A, Osswald L, Yan KL, Weber A, Tugues S, Spath S, Pfeifer D, Follo M, Claus R, Lübbert M, Rummelt C, Bertz H, Wäsch R, Haag J, Schmidts A, Schultheiss M, Bettinger D, Thimme R, Ullrich E, Tanriver Y, Vuong GL, Arnold R, Hemmati P, Wolf D, Ditschkowski M, Jilg C, Wilhelm K, Leiber C, Gerull S, Halter J, Lengerke C, Pabst T, Schroeder T, Kobbe G, Rösler W, Doostkam S, Meckel S, Stabla K, Metzelder SK, Halbach S, Brummer T, Hu Z, Dengjel J, Hackanson B, Schmid C, Holtick U, Scheid C, Spyridonidis A, Stölzel F, Ordemann R, Müller LP, Sicre-de-Fontbrune F, Ihorst G, Kuball J, Ehlert JE, Feger D, Wagner EM, Cahn JY, Schnell J, Kuchenbauer F, Bunjes D, Chakraverty R, Richardson S, Gill S, Kröger N, Ayuk F, Vago L, Ciceri F, Müller AM, Kondo T, Teshima T, Klaeger S, Kuster B, Kim DDH, Weisdorf D, van der Velden W, Dörfel D, Bethge W, Hilgendorf I, Hochhaus A, Andrieux G, Börries M, Busch H, Magenau J, Reddy P, Labopin M, Antin JH, Henden AS, Hill GR, Kennedy GA, Bar M, Sarma A, McLornan D, Mufti G, Oran B, Rezvani K, Shah O, Negrin RS, Nagler A, Prinz M, Burchert A, Neubauer A, Beelen D, Mackensen A, von Bubnoff N, Herr W, Becher B, Socié G, Caligiuri MA, Ruggiero E, Bonini C, Häcker G, Duyster J, Finke J, Pearce E, Blazar BR, Zeiser R.

Nat Med. 2018 Apr 10;24(4):526. doi: 10.1038/nm0418-526c.

PMID:
29634689
27.

Navigating the changing multiple myeloma treatment landscape: clinical practice patterns of MM patients treated in- and outside German DSMM study group trials<sup/>.

Gengenbach L, Reinhardt H, Ihorst G, Ajayi S, Dold SM, Köhler M, Einsele H, Duyster J, Wäsch R, Engelhardt M.

Leuk Lymphoma. 2018 Nov;59(11):2692-2699. doi: 10.1080/10428194.2018.1448084. Epub 2018 Mar 23. No abstract available.

PMID:
29569975
28.

Anti-Angiogenics: Current Situation and Future Perspectives.

Zirlik K, Duyster J.

Oncol Res Treat. 2018;41(4):166-171. doi: 10.1159/000488087. Epub 2018 Mar 23. Review.

29.

Oncogenic JAK2V617F causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms.

Prestipino A, Emhardt AJ, Aumann K, O'Sullivan D, Gorantla SP, Duquesne S, Melchinger W, Braun L, Vuckovic S, Boerries M, Busch H, Halbach S, Pennisi S, Poggio T, Apostolova P, Veratti P, Hettich M, Niedermann G, Bartholomä M, Shoumariyeh K, Jutzi JS, Wehrle J, Dierks C, Becker H, Schmitt-Graeff A, Follo M, Pfeifer D, Rohr J, Fuchs S, Ehl S, Hartl FA, Minguet S, Miething C, Heidel FH, Kröger N, Triviai I, Brummer T, Finke J, Illert AL, Ruggiero E, Bonini C, Duyster J, Pahl HL, Lane SW, Hill GR, Blazar BR, von Bubnoff N, Pearce EL, Zeiser R.

Sci Transl Med. 2018 Feb 21;10(429). pii: eaam7729. doi: 10.1126/scitranslmed.aam7729.

30.

Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells.

Mathew NR, Baumgartner F, Braun L, O'Sullivan D, Thomas S, Waterhouse M, Müller TA, Hanke K, Taromi S, Apostolova P, Illert AL, Melchinger W, Duquesne S, Schmitt-Graeff A, Osswald L, Yan KL, Weber A, Tugues S, Spath S, Pfeifer D, Follo M, Claus R, Lübbert M, Rummelt C, Bertz H, Wäsch R, Haag J, Schmidts A, Schultheiss M, Bettinger D, Thimme R, Ullrich E, Tanriver Y, Vuong GL, Arnold R, Hemmati P, Wolf D, Ditschkowski M, Jilg C, Wilhelm K, Leiber C, Gerull S, Halter J, Lengerke C, Pabst T, Schroeder T, Kobbe G, Rösler W, Doostkam S, Meckel S, Stabla K, Metzelder SK, Halbach S, Brummer T, Hu Z, Dengjel J, Hackanson B, Schmid C, Holtick U, Scheid C, Spyridonidis A, Stölzel F, Ordemann R, Müller LP, Sicre-de-Fontbrune F, Ihorst G, Kuball J, Ehlert JE, Feger D, Wagner EM, Cahn JY, Schnell J, Kuchenbauer F, Bunjes D, Chakraverty R, Richardson S, Gill S, Kröger N, Ayuk F, Vago L, Ciceri F, Müller AM, Kondo T, Teshima T, Klaeger S, Kuster B, Kim DDH, Weisdorf D, van der Velden W, Dörfel D, Bethge W, Hilgendorf I, Hochhaus A, Andrieux G, Börries M, Busch H, Magenau J, Reddy P, Labopin M, Antin JH, Henden AS, Hill GR, Kennedy GA, Bar M, Sarma A, McLornan D, Mufti G, Oran B, Rezvani K, Shah O, Negrin RS, Nagler A, Prinz M, Burchert A, Neubauer A, Beelen D, Mackensen A, von Bubnoff N, Herr W, Becher B, Socié G, Caligiuri MA, Ruggiero E, Bonini C, Häcker G, Duyster J, Finke J, Pearce E, Blazar BR, Zeiser R.

Nat Med. 2018 Mar;24(3):282-291. doi: 10.1038/nm.4484. Epub 2018 Feb 12. Erratum in: Nat Med. 2018 Apr 10;24(4):526.

31.

Cell-free DNA characteristics and chimerism analysis in patients after allogeneic cell transplantation.

Duque-Afonso J, Waterhouse M, Pfeifer D, Follo M, Duyster J, Bertz H, Finke J.

Clin Biochem. 2018 Feb;52:137-141. doi: 10.1016/j.clinbiochem.2017.11.015. Epub 2017 Nov 24.

PMID:
29180242
32.

Microenvironmental stromal cells abrogate NF-κB inhibitor-induced apoptosis in chronic lymphocytic leukemia.

Simon-Gabriel CP, Foerster K, Saleem S, Bleckmann D, Benkisser-Petersen M, Thornton N, Umezawa K, Decker S, Burger M, Veelken H, Claus R, Dierks C, Duyster J, Zirlik K.

Haematologica. 2018 Jan;103(1):136-147. doi: 10.3324/haematol.2017.165381. Epub 2017 Nov 9.

33.

Stem cell mobilization in poor mobilizers with multiple myeloma or lymphoma before and after introduction of plerixafor: a single-center comparative analysis using a cost-efficient single fixed-dose schedule.

Greil C, Ihorst G, Kiote-Schmidt C, Hildenbeutel S, Kühbach K, Bosse R, Duyster J, Engelhardt M, Wäsch R.

Leuk Lymphoma. 2018 Jul;59(7):1722-1725. doi: 10.1080/10428194.2017.1393673. Epub 2017 Oct 30. No abstract available.

PMID:
29081261
34.

The oligodendrocyte lineage transcription factor 2 (OLIG2) is epigenetically regulated in acute myeloid leukemia.

Yalcin A, Kovarbasic M, Wehrle J, Claus R, Becker H, Abdelkarim M, Gaidzik VI, Schmidts A, Wäsch R, Pahl HL, Döhner K, Bullinger L, Duyster J, Lübbert M, Hackanson B.

Exp Hematol. 2017 Nov;55:76-85.e3. doi: 10.1016/j.exphem.2017.07.009. Epub 2017 Jul 28.

PMID:
28760688
35.

CXCL12 and CXCR7 are relevant targets to reverse cell adhesion-mediated drug resistance in multiple myeloma.

Waldschmidt JM, Simon A, Wider D, Müller SJ, Follo M, Ihorst G, Decker S, Lorenz J, Chatterjee M, Azab AK, Duyster J, Wäsch R, Engelhardt M.

Br J Haematol. 2017 Oct;179(1):36-49. doi: 10.1111/bjh.14807. Epub 2017 Jul 2.

PMID:
28670693
36.

Favourable outcomes of poor prognosis diffuse large B-cell lymphoma patients treated with dose-dense Rituximab, high-dose Methotrexate and six cycles of CHOP-14 compared to first-line autologous transplantation.

Strüßmann T, Fritsch K, Baumgarten A, Fietz T, Engelhardt M, Mertelsmann R, Ihorst G, Duyster J, Finke J, Marks R.

Br J Haematol. 2017 Sep;178(6):927-935. doi: 10.1111/bjh.14802. Epub 2017 Jun 23.

PMID:
28643323
37.

FLT3 and FLT3-ITD phosphorylate and inactivate the cyclin-dependent kinase inhibitor p27Kip1 in acute myeloid leukemia.

Peschel I, Podmirseg SR, Taschler M, Duyster J, Götze KS, Sill H, Nachbaur D, Jäkel H, Hengst L.

Haematologica. 2017 Aug;102(8):1378-1389. doi: 10.3324/haematol.2016.160101. Epub 2017 May 18.

38.

MicroRNA-146a reduces MHC-II expression via targeting JAK/STAT signaling in dendritic cells after stem cell transplantation.

Stickel N, Hanke K, Marschner D, Prinz G, Köhler M, Melchinger W, Pfeifer D, Schmitt-Graeff A, Brummer T, Heine A, Brossart P, Wolf D, von Bubnoff N, Finke J, Duyster J, Ferrara J, Salzer U, Zeiser R.

Leukemia. 2017 Dec;31(12):2732-2741. doi: 10.1038/leu.2017.137. Epub 2017 May 9.

39.

Biglycan expression in the melanoma microenvironment promotes invasiveness via increased tissue stiffness inducing integrin-β1 expression.

Andrlová H, Mastroianni J, Madl J, Kern JS, Melchinger W, Dierbach H, Wernet F, Follo M, Technau-Hafsi K, Has C, Rao Mittapalli V, Idzko M, Herr R, Brummer T, Ungefroren H, Busch H, Boerries M, Narr A, Ihorst G, Vennin C, Schmitt-Graeff A, Minguet S, Timpson P, Duyster J, Meiss F, Römer W, Zeiser R.

Oncotarget. 2017 Jun 27;8(26):42901-42916. doi: 10.18632/oncotarget.17160.

40.

Computational analysis of ABL kinase mutations allows predicting drug sensitivity against selective kinase inhibitors.

Kamasani S, Akula S, Sivan SK, Manga V, Duyster J, Vudem DR, Kancha RK.

Tumour Biol. 2017 May;39(5):1010428317701643. doi: 10.1177/1010428317701643.

PMID:
28475010
41.

Proteasome inhibition enhances the efficacy of volasertib-induced mitotic arrest in AML in vitro and prolongs survival in vivo.

Schnerch D, Schüler J, Follo M, Felthaus J, Wider D, Klingner K, Greil C, Duyster J, Engelhardt M, Wäsch R.

Oncotarget. 2017 Mar 28;8(13):21153-21166. doi: 10.18632/oncotarget.15503.

42.

Paving the Way for Dose Banding of Chemotherapy: An Analytical Approach.

Reinhardt H, Trittler R, Eggleton AG, Wöhrl S, Epting T, Buck M, Kaiser S, Jonas D, Duyster J, Jung M, Hug MJ, Engelhardt M.

J Natl Compr Canc Netw. 2017 Apr;15(4):484-493.

PMID:
28404759
43.

Early mixed hematopoietic chimerism detection by digital droplet PCR in patients undergoing gender-mismatched hematopoietic stem cell transplantation.

Waterhouse M, Pfeifer D, Follo M, Duyster J, Schäfer H, Bertz H, Finke J.

Clin Chem Lab Med. 2017 Jul 26;55(8):1115-1121. doi: 10.1515/cclm-2016-0900.

PMID:
28099121
44.

Successful peripheral blood stem cell mobilization with a cost-efficient single fixed-dose plerixafor schedule in poor mobilizers.

Greil C, Kiote-Schmidt C, Fink G, Ihorst G, Hildenbeutel S, Bosse R, Duyster J, Engelhardt M, Wäsch R.

Leuk Lymphoma. 2017 Aug;58(8):1849-1858. doi: 10.1080/10428194.2016.1271946. Epub 2017 Jan 13.

PMID:
28084849
45.

Evaluating the impact of genetic and epigenetic aberrations on survival and response in acute myeloid leukemia patients receiving epigenetic therapy.

Hiller JK, Schmoor C, Gaidzik VI, Schmidt-Salzmann C, Yalcin A, Abdelkarim M, Blagitko-Dorfs N, Döhner K, Bullinger L, Duyster J, Lübbert M, Hackanson B.

Ann Hematol. 2017 Apr;96(4):559-565. doi: 10.1007/s00277-016-2912-7. Epub 2017 Jan 5.

PMID:
28058491
46.

Spleen Tyrosine Kinase Is Involved in the CD38 Signal Transduction Pathway in Chronic Lymphocytic Leukemia.

Benkisser-Petersen M, Buchner M, Dörffel A, Dühren-von-Minden M, Claus R, Kläsener K, Leberecht K, Burger M, Dierks C, Jumaa H, Malavasi F, Reth M, Veelken H, Duyster J, Zirlik K.

PLoS One. 2016 Dec 30;11(12):e0169159. doi: 10.1371/journal.pone.0169159. eCollection 2016.

47.

Molecular Genetic Characterization of Individual Cancer Cells Isolated via Single-Cell Printing.

Riba J, Renz N, Niemöller C, Bleul S, Pfeifer D, Stosch JM, Metzeler KH, Hackanson B, Lübbert M, Duyster J, Koltay P, Zengerle R, Claus R, Zimmermann S, Becker H.

PLoS One. 2016 Sep 22;11(9):e0163455. doi: 10.1371/journal.pone.0163455. eCollection 2016.

48.

Anti-thymocyte globulin-induced hyperbilirubinemia in patients with myelofibrosis undergoing allogeneic hematopoietic cell transplantation.

Ecsedi M, Schmohl J, Zeiser R, Drexler B, Halter J, Medinger M, Duyster J, Kanz L, Passweg J, Finke J, Bethge W, Lengerke C.

Ann Hematol. 2016 Oct;95(10):1627-36. doi: 10.1007/s00277-016-2758-z. Epub 2016 Aug 2.

PMID:
27480090
49.

Suppression of APC/CCdh1 has subtype specific biological effects in acute myeloid leukemia.

Ewerth D, Schmidts A, Hein M, Schnerch D, Kvainickas A, Greil C, Duyster J, Engelhardt M, Wäsch R.

Oncotarget. 2016 Jul 26;7(30):48220-48230. doi: 10.18632/oncotarget.10196.

50.

Single cell genotyping of exome sequencing-identified mutations to characterize the clonal composition and evolution of inv(16) AML in a CBL mutated clonal hematopoiesis.

Niemöller C, Renz N, Bleul S, Blagitko-Dorfs N, Greil C, Yoshida K, Pfeifer D, Follo M, Duyster J, Claus R, Ogawa S, Lübbert M, Becker H.

Leuk Res. 2016 Aug;47:41-6. doi: 10.1016/j.leukres.2016.05.008. Epub 2016 May 12.

PMID:
27244256

Supplemental Content

Loading ...
Support Center